title: Clinicopathologic correlations of stage IE/IIE primary thyroid diffuse large B-cell lymphoma.
abstract: BACKGROUND
  We studied the clinicopathological characteristics and prognoses of localized stage thyroid diffuse large B-cell lymphoma (DLBCL).
  
  
  METHODS
  This study included 32 patients with stage I/IIE thyroid DLBCL. Their median age was 66 years, the male/female ratio was 10/22.
  
  
  RESULTS
  As to the cellular immunophenotype, CD20 was positive in 31/32, CD5 in 0/32, CD10 in 4/32, CD23 in 1/32, BCL2 in 14/30, and BCL6 in 24/32. Twelve cases showed abnormal karyotypes: two cases with t(8;14)(q24;q32), four cases with 3q27, two cases with 17p11, and four cases with other abnormal karyotypes. As for treatment, eight cases were treated with chemotherapy alone and 24 cases were treated with chemotherapy followed by radiotherapy. Complete response was achieved in 94%. The 5-year progression-free survival was 84% and the 5-year overall survival was 90% with a median follow-up period of 62 months. The germinal center B-cell (GCB) type had a significantly better prognosis than the non-GCB type.
  
  
  CONCLUSIONS
  Localized stage thyroid DLBCL is a disease with a relatively good prognosis. It is, however, a heterogeneous disease with regard to histological type and pathological state. Localized stage thyroid DLBCL has a good prognosis and it is that there are more GCB-type DLBCL lymphomas.
authors.affiliation: Division of Hematology, Department of Internal Medicine, Saitama Medical University, Saitama, Japan. nniitsu@saitama-med.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Niitsu
authors.forename: M
authors.initials: M
authors.lastname: Okamoto
authors.forename: N
authors.initials: N
authors.lastname: Nakamura
authors.forename: H
authors.initials: H
authors.lastname: Nakamine
authors.forename: M
authors.initials: M
authors.lastname: Bessho
authors.forename: M
authors.initials: M
authors.lastname: Hirano
mesh_terms: D000368:Aged; D018951:Antigens, CD20 / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols; D018956:CD5 Antigens / Q000378:metabolism; D002869:Chromosome Aberrations; D003131:Combined Modality Therapy; D004268:DNA-Binding Proteins / Q000378:metabolism; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D009367:Neoplasm Staging; D015260:Neprilysin / Q000378:metabolism; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D051560:Proto-Oncogene Proteins c-bcl-6; D011878:Radiotherapy; D017455:Receptors, IgE / Q000378:metabolism; D016019:Survival Analysis; D013964:Thyroid Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*
chemical_list: D018951:Antigens, CD20; C084103:BCL6 protein, human; D018956:CD5 Antigens; D004268:DNA-Binding Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D051560:Proto-Oncogene Proteins c-bcl-6; D017455:Receptors, IgE; D015260:Neprilysin